Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Atherosclerosis Risk Refinement - a Multi-marker Approach Using Microarrays|
- SA burden, as indicated by coronary artery calcium score and intima-medial thickness [ Time Frame: Measured at completion of sample analysis ] [ Designated as safety issue: No ]
|Study Start Date:||March 2007|
|Study Completion Date:||February 2010|
|Primary Completion Date:||August 2007 (Final data collection date for primary outcome measure)|
Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with significant subclinical atherosclerosis (SA) and a low Framingham risk score
Participants from MESA with no SA and a low Framingham risk score
Healthy participants from Northwestern University
CVD is the leading cause of death worldwide and accounts for almost 40% of deaths each year in the United States. In a person with CVD, oxygenated blood is not adequately distributed throughout the body because of impaired function in the heart and blood vessels. This restricted blood flow can eventually lead to organ damage, heart attack, and stroke. Risk prediction for CVD, which is largely associated with SA, relies on the use of certain traditional risk factors. The widely used Framingham risk score (FRS) has provided excellent risk discrimination and reliable estimates of 10-year risk for CVD, but it does not account for the genetics behind SA. Although numerous studies have investigated novel genetic biomarkers to attempt to add predictive value to the FRS, no single biomarker to date has been able to improve risk prediction in a meaningful way. A multi-marker approach that identifies several novel markers unrelated to traditional risk factors may be more effective in improving the identification of those at risk for CVD. This study will first construct a multi-marker approach that is based on patterns of gene expression in peripheral blood leukocytes (PBLs) and that can serve to identify people with substantial SA. The study will then use this approach to determine whether gene expression patterns of PBLs in people with SA are distinct from those in people without SA.
This study will use previously collected data and specimens, including blood samples and SA imaging, from participants in the Multi-Ethnic Study of Atherosclerosis (MESA) trial and from healthy female participants from Northwestern University. Blood samples will be used for analysis of patterns of gene expression in PBLs. There will be no new study visits for this study.
The study completion date listed in this record was obtained from the "Completed Date" entered in the Query View Report System (QVR).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00613158
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Principal Investigator:||Chiang-Ching Huang, PhD||Northwestern University|